Blue genes.
- Published in:
- Marketing Health Services, 2007, v. 27, n. 4, p. 8
- Publication type:
- Article
Works matching DE "FOREST Laboratories Inc."
Results: 22
1
2
Pediatric Lexapro approved.
- Published in:
- Contemporary Pediatrics, 2009, v. 26, n. 4, p. 16
- Publication type:
- Article
3
News Updates.
- Published in:
- Brown University Psychopharmacology Update, 2003, v. 14, n. 11, p. 7
- Publication type:
- Article
4
Non-approvable letter for acamprosate.
- Published in:
- Brown University Psychopharmacology Update, 2002, v. 13, n. 8, p. 7
- Publication type:
- Article
5
U.S. right for acamprosate obtained by Forest.
- Published in:
- Brown University Psychopharmacology Update, 2001, v. 12, n. 11, p. 8
- Publication type:
- Article
6
Forest Under Fire.
- Published in:
- Psychiatric Times, 2009, v. 26, n. 4, p. 1
- By:
- Publication type:
- Article
7
Newsbriefs.
- Published in:
- American Journal of Alzheimer's Disease & Other Dementias, 2005, v. 20, n. 5, p. 264, doi. 10.1177/153331750502000507
- Publication type:
- Article
8
FDA SAYS NO TO FOREST'S NAMENDA FOR MILD ALZHEIMER'S.
- Published in:
- Applied Clinical Trials, 2005, v. 14, n. 9, p. 21
- Publication type:
- Article
9
Actavis buys Forest for US$25bn.
- Published in:
- TCE: The Chemical Engineer, 2014, n. 873, p. 8
- Publication type:
- Article
10
Neramexane.
- Published in:
- Drugs in R&D, 2002, v. 3, n. 1, p. 19, doi. 10.2165/00126839-200203010-00003
- Publication type:
- Article
11
Oxycodone/Ibuprofen.
- Published in:
- Drugs in R&D, 2002, v. 3, n. 1, p. 56, doi. 10.2165/00126839-200203010-00013
- Publication type:
- Article
12
U.S. NEUROPATHIC PAIN MARKET VALUE PREDICITED TO DOUBLE TO $5 BILLION BY 2018.
- Published in:
- Journal of Pain & Palliative Care Pharmacotherapy, 2008, v. 22, n. 4, p. 368
- Publication type:
- Article
13
Benicar.
- Published in:
- Formulary, 2002, v. 37, n. 6, p. 270
- Publication type:
- Article
14
New β-blocker gets FDA approval.
- Published in:
- American Journal of Health-System Pharmacy, 2008, v. 65, n. 3, p. 190, doi. 10.2146/news080009
- By:
- Publication type:
- Article
15
Infacol preferred health visitors' treatment for infant colic.
- Published in:
- British Journal of Midwifery, 2004, v. 12, n. 5, p. 336
- Publication type:
- Article
16
FOREST LABORATORIES, INC. AND GEDEON RICHTER ANNOUNCE POSITIVE RESULTS FROM A PHASE IIB STUDY OF CARIPRAZINE FOR THE TREATMENT OF SCHIZOPHRENIA.
- Published in:
- Psychiatry (1550-5952), 2009, v. 6, n. 11, p. 11
- Publication type:
- Article
17
USPTO ISSUES NOTICE OF FINAL DETERMINATION FOR PATENT TERM EXTENSION FOR NAMENDA.
- Published in:
- Psychiatry (1550-5952), 2009, v. 6, n. 3, p. 14
- Publication type:
- Article
18
MISNAMING OF ARBITRAL AGENCY--INTER-AMERICAN COMMERCIAL ARBITRATION COMMISSION--NEW YORK.
- Published in:
- Arbitration Journal, 1968, v. 23, n. 3, p. 191
- Publication type:
- Article
19
Campral Safe for Treating Alcohol Dependence.
- Published in:
- Journal of Psychosocial Nursing & Mental Health Services, 2005, v. 43, n. 7, p. 12
- Publication type:
- Article
20
Phase III study: Escitalopram improves depressive symptoms in teens.
- Published in:
- Brown University Child & Adolescent Psychopharmacology Update, 2008, v. 10, n. 7, p. 8
- Publication type:
- Article
21
News Notes.
- Published in:
- Brown University Child & Adolescent Psychopharmacology Update, 2004, v. 6, n. 1, p. 8
- Publication type:
- Article
22
News Update.
- Published in:
- Brown University Child & Adolescent Psychopharmacology Update, 2002, v. 4, n. 2, p. 8
- Publication type:
- Article